Shamburg News · 8-K filed Nov 6, 2026, 8:00 AM EST
Acrivon Therapeutics Acquires ACR-525 JAK1 Inhibitor and PKCθ Program from Aqilion AB
ACRV · Acrivon Therapeutics, Inc.
- Acquisition
- Material agreement
- Other event
- Materiality: medium
Acrivon Therapeutics, Inc. entered into an asset purchase agreement with Aqilion AB under which it acquired programs for oral JAK1 inhibitors, including ACR-525 (formerly AQ280), and a PKCθ inhibitor preclinical program. The Company paid an undisclosed cash consideration and has no further milestone or royalty obligations, and the transaction closed concurrently with signing. Concurrently, Aqilion and LEO Pharma terminated royalty and milestone obligations on ACR-525. The Company announced the transaction in a press release dated November 6, 2026, and plans a webcast on November 10, 2026.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-450779.
Written from the filing by Shamburg Markets. Figures are as reported by the company.